Full-Time
Posted on 1/29/2025
Develops durable genetic treatments for diseases
No salary listed
Mid, Senior
Cambridge, MA, USA
Generation Bio focuses on developing long-lasting and repeatable genetic treatments for both rare and common diseases. The company utilizes a unique non-viral genetic medicine platform that includes iqDNA, which is designed to avoid triggering immune responses, and ctLNP, a delivery system that targets specific cells using lipid nanoparticles. Their manufacturing process, called rapid enzymatic synthesis (RES), allows for the efficient production of iqDNA, enabling the delivery of large amounts of genetic material to targeted tissues. This process not only aims to provide durable effects from a single treatment but also allows for adjustments in treatment through redosing. Generation Bio stands out from competitors by offering scalable production capabilities that can potentially yield hundreds of millions of doses, making genetic medicine more accessible. The company's goal is to address significant medical needs by developing effective genetic therapies for a wide range of diseases.
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET.A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.About Generation BioGeneration Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.For more information, please visit www.generationbio.com.Investors and Media Contact
Generation Bio Co. ends lease citing landlord breach.
Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell types. Development of immune-quiet DNA (iqDNA) platform for lead hemophilia A program to continueStrategic reorganization will result in a 40% reduction of workforce . Anticipated cost savings to extend cash runway into 2H 2027
Loading. Loading. Loading...– Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and tolerability comparable to mRNA– Company is advancing iqDNA in lieu of prior ceDNA constructs across all programs, including its lead program in hemophilia A– Company is extending cash runway guidance into 2026 through collaboration income and expense control while increasing investment in its iqDNA and cell-targeted lipid nanoparticle (ctLNP) platforms– Company will present data on iqDNA and ctLNP platforms at upcoming scientific meetings today and on October 26, and will host a webcast R&D event on November 1CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. GBIO, a biotechnology company developing genetic medicines for people living with rare and prevalent diseases, today announced the development of a proprietary, novel DNA called immune-quiet DNA (iqDNA). iqDNA is an optimized variant of the company's closed-ended DNA (ceDNA) that upon systemic administration with Generation Bio's lipid nanoparticle (LNP) delivery has shown cytokine levels and tolerability comparable to chemically modified messenger RNA (mRNA) in mice and non-human primates (NHPs).Generation Bio's non-viral genetic medicine platform aims to advance durable, redosable, and titratable therapies to reach potentially hundreds of millions of patients worldwide